CORRELATION BETWEEN THE EXPRESSION LEVEL OF LIMD2 AND E-CADHERIN IN NON-SMALL CELL LUNG CANCER

Objective: To study the correlation between the expression level of LIMD2 and E-cadherin in non-small cell lung cancer. Methods: A total of 143 NSCLC pathological tissue specimens and 27 normal tissue samples were collected in our hospital from May 2017 to October 2018. The tissue specimens were fixed with 10% formaldehyde and embedded in paraffin. The immunohistochemical method was used to detect the expression of LIMD2 protein and E-cadherin in NSCLC tissues and normal adjacent tissues, and to analyze the correlation between LIMD2 protein, E-cadherin and the clinicopathological features and prognosis of patients. The relationship among the expression levels of LIMD2 protein, E-cadherin and the postoperative prognosis of patients with NSCLC was observed and analyzed. Results: In NSCLC tissues, the high expression rate of LIMD2 was 50.35% and the low expression rate was 49.65%; in normal tissues adjacent to cancer, the high expression rate of LIMD2 was 29.63% and the low expression rate was 70.37%; the expression of LIMD2 in NSCLC tissues was significantly higher than in normal tissues adjacent to cancer (P< 0.05). In NSCLC tissues, the high expression rate of E-cadherin was 53.15% and the low expression rate was 46.85%; in the adjacent tissues, the high expression rate of E-cadherin was 51.85% and the low expression rate was 48.15%; there was no statistically significant difference in E-cadherin expression between normal tissues and tissues adjacent to cancer in NSCLC (P> 0.05). The expression level of LIMD2 was found to be related to gender, lymph node metastasis, TNM staging, and tissue differentiation (P< 0.05), and the expression level of E-cadherin was found to be related to the depth of tumor invasion and lymph node metastasis. The progression-free survival period of patients with the high expression of LIMD2 of (22.31 +/- 1.71) months was significantly shorter than that of patients with the low expression of (30.41 +/- 2.91) months (P< 0.05). The postoperative progression-free survival period of patients with the high expression of E-cadherin of (33.11 +/- 2.91) months was significantly longer than that of patients with low expression (18.11 +/- 2.21) (P< 0.01). Gender, tumor invasion depth, tissue differentiation degree, TNM staging, LIMD2 protein, and E-cadherin expression levels can all be considered independent risk factors affecting the prognosis of gastric cancer patients (P < 0.05). LIMD2 was negatively correlated with E-cadherin expression (P< 0.01). Conclusion: The expression level of LIMD2 was related to the patient's gender, lymph node metastasis, TNM staging, and tissue differentiation; the expression level of E-cadherin was related to the depth of tumor invasion and lymph node metastasis, and the expression of LIMD2 was negatively correlated with the expression of E-cadherin. LIMD2 may inhibit the expression of E-cadherin, which can be used as an important marker for evaluating the prognosis of patients with NSCLC.